{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:23:46Z","timestamp":1788067426302,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.anpede.2025.503857","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:25:27Z","timestamp":1747214727000},"page":"503857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in the treatment of cystic fibrosis: CFTR modulators"],"prefix":"10.1016","volume":"102","author":[{"given":"Maria Dolores","family":"Pastor-Vivero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Costa i Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00edn de Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saioa","family":"Vicente-Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Garcia Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonz\u00e1lez Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Luna Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpede.2025.503857_bib0005","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"18","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anpede.2025.503857_bib0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.anpede.2025.503857_bib0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpede.2025.503857_bib0020","first-page":"1","article-title":"Registro Espa\u00f1ol de Fibrosis Qu\u00edstica","volume":"2025","author":"Pastor-Vivero","year":"2022","journal-title":"Informe anual"},{"issue":"18","key":"10.1016\/j.anpede.2025.503857_bib0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMc1510466","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.anpede.2025.503857_bib0030","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"Lumacaftor\/Ivacaftor in patients aged 6-11 years with Cystic Fibrosis homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anpede.2025.503857_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med."},{"issue":"21","key":"10.1016\/j.anpede.2025.503857_bib0040","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1016\/j.anpede.2025.503857_bib0045","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med."},{"issue":"17","key":"10.1016\/j.anpede.2025.503857_bib0050","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpede.2025.503857_bib0055","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.anpede.2025.503857_bib0060","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"10.1016\/j.anpede.2025.503857_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"issue":"24","key":"10.1016\/j.anpede.2025.503857_bib0070","first-page":"00411","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"S2213-2600","author":"Keating","year":"2024","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpede.2025.503857_bib0075","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpede.2025.503857_bib0080","series-title":"Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report","year":"2023"},{"key":"10.1016\/j.anpede.2025.503857_bib0085","series-title":"European Cystic Fibrosis Society Patient Registry 2022 Annual Data Report","author":"Zolin","year":"2023"},{"issue":"10","key":"10.1016\/j.anpede.2025.503857_bib0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thorax-2023-220558","article-title":"Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis","volume":"79","author":"Merlo","year":"2024","journal-title":"Thorax."},{"issue":"3","key":"10.1016\/j.anpede.2025.503857_bib0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.anpedi.2018.05.022","article-title":"Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation","volume":"90","author":"Gomez-Pastrana","year":"2019","journal-title":"An Pediatr (Engl Ed)."},{"issue":"8","key":"10.1016\/j.anpede.2025.503857_bib0100","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr Pulmonol."},{"issue":"9","key":"10.1016\/j.anpede.2025.503857_bib0105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older \u2013 The RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0110","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/j.jcf.2021.08.003","article-title":"The impact of modulator therapy in cystic fibrosis on patterns of hospitalization related to age. Results from an analysis of US inpatient episodes 2006\u20132016","volume":"20","author":"Nguyen","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.anpede.2025.503857_bib0115","article-title":"Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy","volume":"11","author":"Burgel","year":"2024","journal-title":"BMJ Open Respir Res."},{"issue":"1","key":"10.1016\/j.anpede.2025.503857_bib0120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00330-023-09912-6","article-title":"Effect of CFTR modulator therapy with elexacaftor\/tezacaftor\/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients","volume":"34","author":"Klime\u0161","year":"2024","journal-title":"Eur Radiol."},{"issue":"2","key":"10.1016\/j.anpede.2025.503857_bib0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcf.2023.08.009","article-title":"Chronic rhinosinusitis in the era of CFTR modulator therapy","volume":"23","author":"Stone","year":"2024","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.anpede.2025.503857_bib0130","article-title":"Assessment of cystic fibrosis related liver disease in a pediatric cohort","author":"Vicente-Santamar\u00eda","year":"2024","journal-title":"Gastroenterol Hepatol."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0135","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jcf.2024.03.011","article-title":"Elexacaftor\/tezacaftor\/ivacaftor use in pediatric cystic fibrosis patients with advanced liver disease","volume":"23","author":"Protich","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/ppul.26970","article-title":"SHIFTing goals in cystic fibrosis\u2014managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium","volume":"59","author":"O\u2019Donnell","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 2","key":"10.1016\/j.anpede.2025.503857_bib0145","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcf.2017.07.014","article-title":"Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine","volume":"16","author":"Dorsey","year":"2017","journal-title":"J Cyst Fibros."},{"key":"10.1016\/j.anpede.2025.503857_bib0150","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol."},{"issue":"1","key":"10.1016\/j.anpede.2025.503857_bib0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep."},{"issue":"7","key":"10.1016\/j.anpede.2025.503857_bib0160","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/pedi.12026","article-title":"Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study","volume":"14","author":"Bellin","year":"2013","journal-title":"Pediatr Diabetes."},{"issue":"2","key":"10.1016\/j.anpede.2025.503857_bib0170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0175","article-title":"Future comorbidities in an aging cystic fibrosis population","volume":"13","author":"Ticona","year":"2023","journal-title":"Life (Basel)."},{"issue":"5","key":"10.1016\/j.anpede.2025.503857_bib0180","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2024.07.012","article-title":"The clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor (ETI) for people with CF without a F508del variant: a systematic review and meta-analysis","volume":"23","author":"Lupas","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"2","key":"10.1016\/j.anpede.2025.503857_bib0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther."},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0190","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"1","key":"10.1016\/j.anpede.2025.503857_bib0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jcf.2023.07.003","article-title":"Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI","volume":"23","author":"De Wachter","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.anpede.2025.503857_bib0200","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J Cyst Fibros."}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287925001322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287925001322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:35:33Z","timestamp":1747740933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2341287925001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2341287925001322"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503857","relation":{},"ISSN":["2341-2879"],"issn-type":[{"value":"2341-2879","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of cystic fibrosis: CFTR modulators","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2025.503857","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"503857"}}